血浆神经酰胺水平与射血分数减低型心力衰竭的相关性
The Correlation between Plasma Ceramide Levels and Reduced Ejection Fraction Heart Failure
摘要: 目的：旨在研究血浆神经酰胺水平在射血分数减低型心力衰竭患者中的变化，以及神经酰胺与HFrEF患者心功能的相关性及预测价值。方法：采用1:1病例对照研究方法，收集了青岛大学附属医院心血管内科在2023年1月至2024年3月期间，门诊和住院的98例射血分数减低型心力衰竭患者作为病例组，并选取了98例健康体检中心的患者作为对照组。检测血浆中6种神经酰胺(Cer16:0、Cer18:0、Cer20:0、Cer22:0、Cer24:0、Cer24:1)的水平，分析血浆神经酰胺对HFrEF的辅助诊断价值。结果：研究显示Cer16:0、Cer18:0、Cer20:0和Cer22:0在病例组表现出高表达，并且与NT-proBNP水平呈正相关；Cer24:0在HFrEF患者中的表达较低，并与NT-proBNP水平呈负相关，差异具有统计学意义(p < 0.05)。ROC曲线分析结果显示Cer16:0、Cer18:0、Cer20:0和Cer22:0的AUC值均>0.9，对HFrEF具有较高的诊断价值。结论：Cer16:0、Cer18:0、Cer20:0和Cer22:0水平变化可反映HFrEF心功能严重程度，可以考虑作为诊断HFrEF的生物标志物。
Abstract: Objective: The study aims to investigate the changes in plasma ceramide levels in patients with heart failure with reduced ejection fraction (HFrEF) and the correlation and predictive value of ceramides with cardiac function in HFrEF patients. Methods: Through a case-control study method, 98 patients with heart failure with reduced ejection fraction who visited and were hospitalized at the Department of Cardiology, Affiliated Hospital of Qingdao University, from January 2023 to March 2024 were collected as the case group, and 98 healthy individuals from the health examination center were selected as the control group. The levels of six types of ceramides (Cer16:0, Cer18:0, Cer20:0, Cer22:0, Cer24:0, Cer24:1) in the plasma were detected, and the auxiliary diagnostic value of plasma ceramides for HFrEF was analyzed. Results: Studies have shown that Cer16:0, Cer18:0, Cer20:0, and Cer22:0 exhibit high expression in the case group and are positively correlated with NT-proBNP levels; Cer24:0 expression is lower in HFrEF patients and is negatively correlated with NT-proBNP levels, with statistically significant differences (p < 0.05). ROC curve analysis results indicate that the AUC values for Cer16:0, Cer18:0, Cer20:0, and Cer22:0 are all greater than 0.9, indicating high diagnostic value for HFrEF. Conclusion: Changes in the levels of Cer16:0, Cer18:0, Cer20:0, and Cer22:0 can reflect the severity of heart function in HFrEF and may be considered as biomarkers for the diagnosis of HFrEF.
文章引用：孙建秀, 李娇, 张文忠. 血浆神经酰胺水平与射血分数减低型心力衰竭的相关性[J]. 临床医学进展, 2025, 15(5): 1942-1948. https://doi.org/10.12677/acm.2025.1551578

参考文献

[1] Castro, B.M., Prieto, M. and Silva, L.C. (2014) Ceramide: A Simple Sphingolipid with Unique Biophysical Properties. Progress in Lipid Research, 54, 53-67. [Google Scholar] [CrossRef] [PubMed]
[2] Yang, Q., Vijayakumar, A. and Kahn, B.B. (2018) Metabolites as Regulators of Insulin Sensitivity and Metabolism. Nature Reviews Molecular Cell Biology, 19, 654-672. [Google Scholar] [CrossRef] [PubMed]
[3] 李娟芬, 张慧娜, 钱宗杰. 神经酰胺对心血管疾病及功能影响的研究进展[J]. 心肺血管病杂志, 2016, 35(5): 413-415.
[4] Laaksonen, R., Ekroos, K., Sysi-Aho, M., Hilvo, M., Vihervaara, T., Kauhanen, D., et al. (2016) Plasma Ceramides Predict Cardiovascular Death in Patients with Stable Coronary Artery Disease and Acute Coronary Syndromes beyond LDL-Cholesterol. European Heart Journal, 37, 1967-1976. [Google Scholar] [CrossRef] [PubMed]
[5] Hla, T. and Dannenberg, A.J. (2012) Sphingolipid Signaling in Metabolic Disorders. Cell Metabolism, 16, 420-434. [Google Scholar] [CrossRef] [PubMed]
[6] Chokshi, A., Drosatos, K., Cheema, F.H., Ji, R., Khawaja, T., Yu, S., et al. (2012) Ventricular Assist Device Implantation Corrects Myocardial Lipotoxicity, Reverses Insulin Resistance, and Normalizes Cardiac Metabolism in Patients with Advanced Heart Failure. Circulation, 125, 2844-2853. [Google Scholar] [CrossRef] [PubMed]
[7] Zhao, L., Spassieva, S.D., Jucius, T.J., Shultz, L.D., Shick, H.E., Macklin, W.B., et al. (2011) A Deficiency of Ceramide Biosynthesis Causes Cerebellar Purkinje Cell Neurodegeneration and Lipofuscin Accumulation. PLOS Genetics, 7, e1002063. [Google Scholar] [CrossRef] [PubMed]
[8] Pewzner-Jung, Y., Park, H., Laviad, E.L., Silva, L.C., Lahiri, S., Stiban, J., et al. (2010) A Critical Role for Ceramide Synthase 2 in Liver Homeostasis. Journal of Biological Chemistry, 285, 10902-10910. [Google Scholar] [CrossRef] [PubMed]
[9] Ji, R., Akashi, H., Drosatos, K., Liao, X., Jiang, H., Kennel, P.J., et al. (2017) Increased De Novo Ceramide Synthesis and Accumulation in Failing Myocardium. JCI Insight, 2, e82922. [Google Scholar] [CrossRef] [PubMed]
[10] Law, B.A., Liao, X., Moore, K.S., Southard, A., Roddy, P., Ji, R., et al. (2018) Lipotoxic Very-Long-Chain Ceramides Cause Mitochondrial Dysfunction, Oxidative Stress, and Cell Death in Cardiomyocytes. The FASEB Journal, 32, 1403-1416. [Google Scholar] [CrossRef] [PubMed]
[11] Mantovani, A., Bonapace, S., Lunardi, G., Salgarello, M., Dugo, C., Gori, S., et al. (2018) Association of Plasma Ceramides with Myocardial Perfusion in Patients with Coronary Artery Disease Undergoing Stress Myocardial Perfusion Scintigraphy. Arteriosclerosis, Thrombosis, and Vascular Biology, 38, 2854-2861. [Google Scholar] [CrossRef] [PubMed]
[12] Peterson, L.R., Xanthakis, V., Duncan, M.S., Gross, S., Friedrich, N., Völzke, H., et al. (2018) Ceramide Remodeling and Risk of Cardiovascular Events and Mortality. Journal of the American Heart Association, 7, e007931. [Google Scholar] [CrossRef] [PubMed]
[13] Argraves, K.M., Sethi, A.A., Gazzolo, P.J., Wilkerson, B.A., Remaley, A.T., Tybjaerg-Hansen, A., et al. (2011) S1P, Dihydro-S1p and C24:1-Ceramide Levels in the HDL-Containing Fraction of Serum Inversely Correlate with Occurrence of Ischemic Heart Disease. Lipids in Health and Disease, 10, 70. [Google Scholar] [CrossRef] [PubMed]
[14] Hilvo, M., Meikle, P.J., Pedersen, E.R., Tell, G.S., Dhar, I., Brenner, H., et al. (2019) Development and Validation of a Ceramide and Phospholipid-Based Cardiovascular Risk Estimation Score for Coronary Artery Disease Patients. European Heart Journal, 41, 371-380. [Google Scholar] [CrossRef] [PubMed]

为你推荐